We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Post-Q3 Earnings: Is SNDL Stock a Portfolio Must-Have?
Read MoreHide Full Article
Key Takeaways
SNDL's Q3 2026 sales topped estimates, but its adjusted loss per share was wider than analysts expected.
SNDL repurchased 5.4 million shares and is exploring a C$50 million issuer bid to boost shareholder returns.
SNDL raised its Parallel ownership to 92%, while margin pressure and weak cannabis sales cloud its outlook.
On Tuesday, SNDL Inc. (SNDL - Free Report) reported mixed third-quarter 2026 results. Although sales beat the Zacks Consensus Estimate, adjusted loss per share was wider than anticipated.
The company reported revenues of $170.1 million (~C$238 million), down from $177.4 million (~C$244.2 million) recorded in the year-ago period. Per SNDL, the reported figure declined 2.5% year over year in Canadian-dollar terms. Despite the miss, the adjusted loss narrowed to 3 cents per share from 4 cents in the prior-year quarter.
Though the narrower adjusted loss offers some encouragement, persistent weakness in parts of SNDL's business raises questions about the sustainability of its recovery. Let’s take a closer look at the company’s fundamentals to better understand how to approach the stock following its latest earnings release.
SNDL Strengthens Its Focus on Shareholder Returns
SNDL is stepping up its efforts to return capital to shareholders through continued share repurchases. During the third quarter of 2026, the company repurchased approximately 5.4 million shares for C$10 million. The repurchase activity continued into October, reflecting management's focus on reducing the outstanding share count and returning capital to investors.
The company is also exploring a potential substantial issuer bid (SIB) of up to C$50 million at a price not exceeding C$1.92 (US$1.35) per share. Unlike regular market buybacks, an SIB invites shareholders to tender their shares through a formal offer. If completed and fully subscribed, it could reduce the outstanding share count by more than 10%. However, the offer is yet to commence and remains contingent on obtaining the necessary approvals. SNDL has also clarified that the SIB will not run simultaneously with its regular share repurchase program.
Investment in Parallel Could Expand SNDL's US Medical Cannabis Exposure
SNDL is strengthening its exposure to the U.S. medical cannabis market through its investment in Parallel. Following Parallel's restructuring in July 2026 and a subsequent rights offering, SNDL increased its indirect equity ownership in the business from approximately 67% to 92%. Parallel operates 56 retail locations and three cultivation and manufacturing facilities across Florida, Texas and Massachusetts, giving SNDL access to a broader U.S. operating footprint.
SNDL is evaluating opportunities to convert its indirect economic interests into direct ownership and financial consolidation of eligible U.S. medical cannabis operations. However, this transition remains subject to legal, regulatory, accounting and Nasdaq requirements. Although the investment could enhance SNDL's operating scale and long-term growth prospects, uncertainty persists regarding the timing of consolidation and its potential contribution to reported earnings.
SNDL's Business Outlook Remains Mixed
Net revenues declined 3.5% year over year to C$669.7 million in the first nine months of 2026. The Liquor Retail business, which remains SNDL’s largest revenue contributor, continued to face lower customer traffic amid declining market trends, partly offset by pricing strategies. The segment’s revenues fell 4.4% to C$373.6 million.
Within cannabis, Cannabis Retail revenues were nearly flat at C$246.2 million, as market contraction in Alberta and Ontario weighed on same-store sales, partly offset by new store openings and Value Buds store conversions. However, the company’s Cannabis Operations continued to struggle, mainly due to lower sales to provincial boards and wholesale customers.
SNDL's overall gross margins contracted 220 basis points to 24.9%. The decline largely reflected continued weakness in Cannabis Operations, where lower sales and inventory-related pressures weighed on profitability, offsetting margin improvements in the two retail segments.
Although free cash flow reached a quarterly record of C$20 million in the third quarter, it included a C$10.6 million benefit from the initial unwinding of the company's captive insurance arrangement. For the first nine months of 2026, free cash flow declined 26.4% year over year to C$5.7 million, highlighting the need to assess whether cash generation can improve sustainably once these one-time benefits are exhausted.
To address the weakness, SNDL has exited the unprofitable domestic dried-flower category, reduced its Kelowna facility workforce by more than 30% and initiated a strategic review of Cannabis Operations. Management expects cost-reduction measures to begin benefiting results in the fourth quarter. The successful EU-GMP audit at its Atholville facility could open up international cannabis opportunities. However, formal certification is still pending, and the financial benefits of the facility upgrades are yet to materialize.
Stiff Competition in Targeted Markets
SNDL faces stiff competition from established cannabis players as it seeks to strengthen its presence and expand its international reach.
Tilray Brands (TLRY - Free Report) has a diversified business spanning cannabis, beverages and pharmaceutical distribution. Its international medical cannabis operations and established distribution network strengthen its competitive position as demand for medical cannabis grows in overseas markets.
Aurora Cannabis (ACB - Free Report) is focused on global medical cannabis, with strong positions in Germany and Poland and plans to expand further in the United Kingdom. Its EU-GMP-certified facilities support its efforts to serve international markets.
SNDL Stock Performance & Valuation
Shares of SNDL have lost nearly 22% year to date compared with the industry’s 19% decline.
Image Source: Zacks Investment Research
Bottom-line estimates for 2026 and 2027 have remained consistent in the past seven days.
Image Source: Zacks Investment Research
How to Play SNDL Stock Now?
We recommend a wait-and-watch approach for this Zacks Rank #3 (Hold) company. Though SNDL’s recent initiatives offer potential for long-term growth, the company still has considerable ground to cover before demonstrating a sustainable improvement in its operating performance.
While the proposed SIB and ongoing share repurchases demonstrate management’s commitment to capital returns, the ultimate benefit to shareholders will depend on the company’s ability to balance buybacks with growth investments and improvements in operating performance.
View the Zacks #1 Rank List
Image: Bigstock
Post-Q3 Earnings: Is SNDL Stock a Portfolio Must-Have?
Key Takeaways
On Tuesday, SNDL Inc. (SNDL - Free Report) reported mixed third-quarter 2026 results. Although sales beat the Zacks Consensus Estimate, adjusted loss per share was wider than anticipated.
The company reported revenues of $170.1 million (~C$238 million), down from $177.4 million (~C$244.2 million) recorded in the year-ago period. Per SNDL, the reported figure declined 2.5% year over year in Canadian-dollar terms. Despite the miss, the adjusted loss narrowed to 3 cents per share from 4 cents in the prior-year quarter.
Though the narrower adjusted loss offers some encouragement, persistent weakness in parts of SNDL's business raises questions about the sustainability of its recovery. Let’s take a closer look at the company’s fundamentals to better understand how to approach the stock following its latest earnings release.
SNDL Strengthens Its Focus on Shareholder Returns
SNDL is stepping up its efforts to return capital to shareholders through continued share repurchases. During the third quarter of 2026, the company repurchased approximately 5.4 million shares for C$10 million. The repurchase activity continued into October, reflecting management's focus on reducing the outstanding share count and returning capital to investors.
The company is also exploring a potential substantial issuer bid (SIB) of up to C$50 million at a price not exceeding C$1.92 (US$1.35) per share. Unlike regular market buybacks, an SIB invites shareholders to tender their shares through a formal offer. If completed and fully subscribed, it could reduce the outstanding share count by more than 10%. However, the offer is yet to commence and remains contingent on obtaining the necessary approvals. SNDL has also clarified that the SIB will not run simultaneously with its regular share repurchase program.
Investment in Parallel Could Expand SNDL's US Medical Cannabis Exposure
SNDL is strengthening its exposure to the U.S. medical cannabis market through its investment in Parallel. Following Parallel's restructuring in July 2026 and a subsequent rights offering, SNDL increased its indirect equity ownership in the business from approximately 67% to 92%. Parallel operates 56 retail locations and three cultivation and manufacturing facilities across Florida, Texas and Massachusetts, giving SNDL access to a broader U.S. operating footprint.
SNDL is evaluating opportunities to convert its indirect economic interests into direct ownership and financial consolidation of eligible U.S. medical cannabis operations. However, this transition remains subject to legal, regulatory, accounting and Nasdaq requirements. Although the investment could enhance SNDL's operating scale and long-term growth prospects, uncertainty persists regarding the timing of consolidation and its potential contribution to reported earnings.
SNDL's Business Outlook Remains Mixed
Net revenues declined 3.5% year over year to C$669.7 million in the first nine months of 2026. The Liquor Retail business, which remains SNDL’s largest revenue contributor, continued to face lower customer traffic amid declining market trends, partly offset by pricing strategies. The segment’s revenues fell 4.4% to C$373.6 million.
Within cannabis, Cannabis Retail revenues were nearly flat at C$246.2 million, as market contraction in Alberta and Ontario weighed on same-store sales, partly offset by new store openings and Value Buds store conversions. However, the company’s Cannabis Operations continued to struggle, mainly due to lower sales to provincial boards and wholesale customers.
SNDL's overall gross margins contracted 220 basis points to 24.9%. The decline largely reflected continued weakness in Cannabis Operations, where lower sales and inventory-related pressures weighed on profitability, offsetting margin improvements in the two retail segments.
Although free cash flow reached a quarterly record of C$20 million in the third quarter, it included a C$10.6 million benefit from the initial unwinding of the company's captive insurance arrangement. For the first nine months of 2026, free cash flow declined 26.4% year over year to C$5.7 million, highlighting the need to assess whether cash generation can improve sustainably once these one-time benefits are exhausted.
To address the weakness, SNDL has exited the unprofitable domestic dried-flower category, reduced its Kelowna facility workforce by more than 30% and initiated a strategic review of Cannabis Operations. Management expects cost-reduction measures to begin benefiting results in the fourth quarter. The successful EU-GMP audit at its Atholville facility could open up international cannabis opportunities. However, formal certification is still pending, and the financial benefits of the facility upgrades are yet to materialize.
Stiff Competition in Targeted Markets
SNDL faces stiff competition from established cannabis players as it seeks to strengthen its presence and expand its international reach.
Tilray Brands (TLRY - Free Report) has a diversified business spanning cannabis, beverages and pharmaceutical distribution. Its international medical cannabis operations and established distribution network strengthen its competitive position as demand for medical cannabis grows in overseas markets.
Aurora Cannabis (ACB - Free Report) is focused on global medical cannabis, with strong positions in Germany and Poland and plans to expand further in the United Kingdom. Its EU-GMP-certified facilities support its efforts to serve international markets.
SNDL Stock Performance & Valuation
Shares of SNDL have lost nearly 22% year to date compared with the industry’s 19% decline.
Image Source: Zacks Investment Research
Bottom-line estimates for 2026 and 2027 have remained consistent in the past seven days.
Image Source: Zacks Investment Research
How to Play SNDL Stock Now?
We recommend a wait-and-watch approach for this Zacks Rank #3 (Hold) company. Though SNDL’s recent initiatives offer potential for long-term growth, the company still has considerable ground to cover before demonstrating a sustainable improvement in its operating performance.
While the proposed SIB and ongoing share repurchases demonstrate management’s commitment to capital returns, the ultimate benefit to shareholders will depend on the company’s ability to balance buybacks with growth investments and improvements in operating performance.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.